Key Highlights
- Zoetis has received USDA licensure for Poulvac Procerta HVT-ND-ILT Vaccine for chickens.
- The vaccine provides dual protection against Newcastle disease (ND) and infectious laryngotracheitis (ILT) from a single HVT vector.
- It can be administered in ovo or at day of age, allowing integration into existing hatchery workflows.
- The vaccine is compatible for concurrent use with other Poulvac products.
Zoetis Inc. (NYSE:ZTS), a global leader in animal health, has received a U.S. Department of Agriculture (USDA) license for Poulvac Procerta HVT-ND-ILT, a new vaccine for chickens that provides dual protection against Newcastle disease (ND) and infectious laryngotracheitis (ILT) from a single herpesvirus of turkey (HVT) vector.
What Does the Vaccine Offer?
The vaccine is designed to protect against two economically significant poultry diseases simultaneously from a single vector. Newcastle disease and ILT both pose meaningful threats to poultry flocks, and combining protection into a single administration simplifies vaccination programs. The vaccine can be administered in ovo or at day of age, allowing integration into existing hatchery workflows.
Poulvac Procerta HVT-ND-ILT is compatible for concurrent use with other vaccines in the Poulvac portfolio, giving poultry producers flexibility in designing their vaccination programs.
Why Does This Matter for the Poultry Industry?
Newcastle disease is a contagious viral disease that affects poultry flocks worldwide and can cause significant mortality and production losses. ILT is a respiratory disease that affects chickens and can result in decreased egg production and increased mortality. By combining protection against both diseases into a single vaccine, Zoetis aims to reduce the complexity and number of interventions required during the hatchery process.
Zoetis is headquartered in Parsippany, New Jersey, and generates more than $9 billion in annual Revenue across livestock and companion animal products.
Sector Context
Animal-health companies develop vaccines to manage disease risks in livestock and poultry. Zoetis’ new USDA-licensed product addresses Newcastle disease and infectious laryngotracheitis in chickens.
Risks to Watch
Regulatory licensure does not quantify market uptake or commercial sales. Vaccine use will depend on producer vaccination plans, field requirements and adoption within hatchery workflows.
What to Watch Ahead
The next information to follow includes commercial rollout details, product availability and any company-reported use of Poulvac Procerta HVT-ND-ILT in poultry vaccination programs.






Please wait processing your request...